Cookson Peirce & Co’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$863K Buy
13,837
+3,894
+39% +$246K 0.03% 217
2026
Q2
$573K Buy
9,943
+424
+4% +$24.3K 0.02% 242
2026
Q1
$577K Buy
+9,519
New +$555K 0.02% 225
2023
Q3
– Sell
-11,360
Closed -$726K – 208
2023
Q2
$726K Sell
11,360
-111,244
-91% -$7.46M 0.04% 117
2023
Q1
$8.5M Buy
122,604
+1,147
+0.9% +$80.9K 0.54% 64
2022
Q4
$8.74M Buy
121,457
+101,616
+512% +$7.66M 0.57% 55
2022
Q3
$1.41M Buy
19,841
+1,334
+7% +$96.8K 0.1% 92
2022
Q2
$1.42M Buy
18,507
+11,743
+174% +$894K 0.1% 92
2022
Q1
$494K Buy
+6,764
New +$454K 0.03% 143
2014
Q2
– Sell
-8,750
Closed -$455K – 137
2014
Q1
$455K Buy
8,750
+270
+3% +$14.4K 0.11% 111
2013
Q4
$451K Buy
8,480
+410
+5% +$20.9K 0.12% 101
2013
Q3
$374K Buy
8,070
+3,320
+70% +$146K 0.1% 88
2013
Q2
$213K Buy
+4,750
New +$206K 0.06% 89

Other funds holding BMY

Cookson Peirce & Co's BMY Position: Q3 2026 in Review

Cookson Peirce & Co increased its Bristol-Myers Squibb (BMY) stake by 39% in Q3 2026, buying an estimated $246K and bringing the position to 13,837 shares worth $863K. The position accounts for 0.03% of the portfolio, ranked #217.

Cookson Peirce & Co first reported a position in BMY in Q2 2013 and has held it in 13 quarters since. The position peaked at $8.74M in Q4 2022. 2,533 funds tracked by Wall St. Rank hold BMY as of Q3 2026.

  • Cookson Peirce & Co held 13,837 shares of Bristol-Myers Squibb worth $863K as of Q3 2026.
  • Cookson Peirce & Co bought 3,894 Bristol-Myers Squibb shares in Q3 2026, an estimated $246K.
  • Bristol-Myers Squibb made up 0.03% of Cookson Peirce & Co's portfolio in Q3 2026, its #217 holding.
  • Cookson Peirce & Co first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 13 quarters since.
  • Cookson Peirce & Co's Bristol-Myers Squibb position peaked at $8.74M in Q4 2022.
  • 2,533 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2026.

Based on Cookson Peirce & Co's 13F filing for Q3 2026, filed 30 Oct 2026.